Investor's Business Daily on MSN2 天
Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Sprinting Toward A Profit-Taking Zone
Arcutis Biotherapeutics wants to eliminate a terrible trade-off for patients with skin conditions. Arcutis stock investors are taking notice.